newsfilter
← Latest News
GlobeNewswire·

Codiak BioSciences Announces Program Reprioritization and Corporate Restructuring

– Enrollment continues in Phase 1 clinical trial of IV-administered exoASO™-STAT6 in patients with advanced hepatocellular carcinoma – – Prioritizing vaccine program funded by CEPI and advancement of engEx-A